Table 1.
Study design, demographics, age, malignancies and prior chemotherapy.
| Author & Year | Country * | Design ** | Duration *** | Patients n | Bidirectional n (%) | Sex M (%) | Age † | Malignancies ‡ | Prev. Chemo n (%) |
|---|---|---|---|---|---|---|---|---|---|
| Sundar et al., 2024 [28] | SGP & BEL | PRO I | Jun 20–Nov 22 | 18 | 18 (100%) | 7 (39%) | 65 a [52.5–70.75] | GC | 18 (100%) |
| van de Vlasakker et al., 2024 [29] | NLD | PRO II | Feb 20–Aug 22 | 20 | 20 (100%) | 10 (50%) | 57.5 a (41–70) | CRC, AC | 0 (0%) |
| Casella et al., 2023 [30] | ITA | RETRO | Oct 19–Apr 22 | 42 | 42 (100%) | 15 (36%) | 60.5 a (49–68) | GC | NR |
| Kryh-Jensen et al., 2023 [26] | DNK | RETRO | Jan 16–Feb 23 | 108 | 49 (45%) | 53 (49%) | GC 64 a; PC 61 a; CRC 69 a | GC, PC, CRC | 107 (99%) |
| Kyle et al., 2023 [31] | GBR | PRO | Jan 19–Jan 22 | 5 | 5 (100%) | 2 (40%) | 44 a (34–66) | CRC | 5 (100%) |
| Raoof et al., 2023 [32] | USA | PRO I | Aug 20–Jan 22 | 12 | 12 (100%) | 7 (58%) | 60 a (29–75) | AC, CRC | 12 (100%) |
| Alyami et al., 2021 [33] | FRA | RETRO | NR–Jan 18 | 42 | 42 (100%) | 20 (48%) | 51.5 a (32–74.7) | GC | 42 (100%) |
| Feldbruegge et al., 2021 [34] | DEU | RETRO | Mar 17–May 20 | 50 | 50 (100%) | 28 (56%) | 58 a (31–76) | GC | 50 (100%) |
| Kepenekian et al., 2021 [11] | FRA | RETRO | Jan 16–May 20 | 26 | 26 (100%) | 14 (54%) | 64 a [56–69] | DMPM | 9 (35%) |
| Siebert et al., 2021 [27] | FRA | RETRO | Dec 15–Mar 18 | 134 | 134 (100%) | 60 (45%) | 59.3 a (25–78) | GC, CRC, OC | 134 (100%) |
| Di Giorgio et al., 2020 [35] | ITA | RETRO | Sep 17–Sep 19 | 28 | 26 (93%) | 12 (43%) | 50 a (38–79) | GC | 28 (100%) |
| Gockel et al., 2020 [36] | DEU | PRO | Nov 15–Feb 18 | 13 | 13 (100%) | 6 (46%) | 61 a (49–77) | CRC, AC, small bowel | 12 (66%) |
| Falkenstein et al., 2018 [37] | DEU | RETRO | Feb 13–Jan 17 | 13 | 3 (23%) | 8 (61%) | 58 b [37–75] | HPB | 7 (54%) |
| Larbre et al., 2018 [38] | FRA | RETRO | Dec 15–Sep 17 | 43 | 39 (91%) | 19 (44%) | 59.8 b (33–77.9) | GC, OC, DMPM, PMP | 39 (91%) |
| Alyami et al., 2017 [39] | FRA | RETRO | Dec 15–Dec 16 | 73 | 64 (88%) | 31 (42%) | 57.1 a (32.3–77.9) | GC, CRC, OC, DMPM, PMP | 64 (88%) |
| Farinha et al., 2017 [40] | CHE | RETRO | Jan 15–Apr 16 | 42 | 1 (2%) | 8 (19%) | 66 a (59–73) | GYN, DIG | NR |
| Hilal et al., 2017 [41] | DEU | PRO | Apr 14–May 16 | 84 | 6 (7%) | 0 (0%) | 60.4 b ± 12.2 | GYN | 84 (100%) |
| Khosrawipour et al., 2017 [42] | DEU | RETRO | Jun 15–Jun 17 | 20 | 6 (30%) | 15 (75%) | 60.6 b (49–69) | PC | 20 (100%) |
| Demtroeder et al., 2016 [43] | DEU | RETRO | Oct 12–Feb 14 | 17 | 11 (65%) | 10 (59%) | 59 b ± 12 | CRC | 16 (94%) |
| Khomyakov et al., 2016 [44] | RUS | PRO II | Aug 13–Jul 16 | 31 | 31 (100%) | 9 (29%) | 52 b | GC | 7 (23%) |
| Reymond et al., 2016 [25] | DEU | RETRO | Jul 14–Oct 15 | 3 | 1 (33%) | 1 (33%) | 66.3 b (59–72) | PC, GBC | 3 (100%) |
| Robella et al., 2016 [45] | ITA | RETRO | Jun 15–Feb 16 | 14 | 13 (93%) | NR | (18–78) | GC, CRC, OC, DMPM, PMP | 14 (100%) |
| Total [Mode] | [DEU] | [R: 15 (68%)] | — | 1010 | 742 (73%) | 314 M: 453 F | — | [GC] | 671 (66%) |
* ISO 3166-1 alpha3 reported for each country. ** RETRO = “Retrospective”; PRO = “Prospective”; I Phase 1, II Phase 2. *** Dates shown as Mon YY (e.g., Feb 20 = February 2020). † Age values shown as median a [IQR] (range) or mean b ± SD. ‡ GC = Gastric Cancer; CRC = Colorectal Cancer; AC = Appendiceal Cancer; PC = Pancreatic Cancer; DMPM = Diffuse Malignant Peritoneal Mesothelioma; PMP = Pseudomyxoma Peritonei; OC = Ovarian Cancer; HPB = Hepato-pancreato-biliary; GBC = Gallbladder Cancer; GYN = Gynecological Cancer.